We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMTR
126
DELISTED
9 Meters Biopharma
NMTR
$9.42M 0.1%
428,299
-857,539
-67% -$21.1M
NBP
127
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$9.33M 0.09%
111,120
+92,555
+499% +$6.11M
GYRE icon
128
Gyre Therapeutics
GYRE
$699M
$9.17M 0.09%
282,480
– –
XFOR icon
129
X4 Pharmaceuticals
XFOR
$401M
$8.93M 0.09%
45,795
– –
WHWK
130
Whitehawk Therapeutics
WHWK
$263M
$8.78M 0.09%
346,263
– –
ASLN
131
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$8.32M 0.08%
63,000
– –
ALXO icon
132
ALX Oncology
ALXO
$277M
$8.2M 0.08%
150,000
– –
STRO icon
133
Sutro Biopharma
STRO
$339M
$8.06M 0.08%
43,370
+8,370
+24% +$1.64M
NRIX icon
134
Nurix Therapeutics
NRIX
$2.72B
$7.96M 0.08%
300,000
– –
GLUE icon
135
Monte Rosa Therapeutics
GLUE
$1.14B
$7.95M 0.08%
+350,000
New +$7.13M
LABP
136
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$7.87M 0.08%
68,100
– –
DYN icon
137
Dyne Therapeutics
DYN
$4.68B
$7.36M 0.07%
350,000
– –
OTIC
138
DELISTED
Otonomy, Inc.
OTIC
$7.25M 0.07%
3,250,000
– –
NBTX
139
Nanobiotix
NBTX
$2.09B
$6.89M 0.07%
500,000
– –
ACRS icon
140
Aclaris Therapeutics
ACRS
$885M
$6.36M 0.06%
+362,000
New +$8.22M
RXDX
141
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$6.14M 0.06%
250,000
– –
VERV
142
DELISTED
Verve Therapeutics
VERV
$6.03M 0.06%
+100,000
New +$4.15M
LUNG icon
143
Pulmonx
LUNG
$102M
$5.51M 0.06%
125,000
– –
SBBP
144
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.18M 0.05%
1,744,669
– –
OBIO icon
145
Orchestra BioMed
OBIO
$311M
$5.1M 0.05%
500,000
– –
OGN icon
146
Organon & Co
OGN
$3.61B
$5.05M 0.05%
+166,939
New +$5.5M
SRPT icon
147
Sarepta Therapeutics
SRPT
$2.2B
$5.03M 0.05%
64,700
-135,578
-68% -$10.3M
TARA icon
148
Protara Therapeutics
TARA
$226M
$4.38M 0.04%
450,000
– –
ADAG
149
Adagene
ADAG
$247M
$3.73M 0.04%
275,000
– –
TRML
150
DELISTED
Tourmaline Bio
TRML
$3.63M 0.04%
+24,724
New +$3.79M
4 5
6
7 8

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.